German team attacks cancer cell microtubules with chemo and blue light

Cancer cell with microtubules (in white) highlighted under a green light--Courtesy of LMU

German researchers have come up with an approach for chemotherapy that would allow the medication to be activated inside a patient when hit with light.

Many successful chemotherapeutic drugs interfere with cancer cells' microtubules, which are necessary for their survival. The researchers from Ludwig-Maximilians-Universität München identified these structures and replaced them with elements that would respond to a blue light, hindering the cells' activity.

The photostatins that inhibit this activity can be activated without affecting other cells. And they could be used in many different settings--because they require only blue light, a patient could wear specialized glasses, for instance, to get the chemotherapy started on his or her eyes. Or wear a bandage with blue sensitivity to attack skin cancer.

The same cancer cell under blue light, with fewer microtubules active, thus inhibiting the cell's activity--Courtesy of LMU

"We can then use light to switch the hinged drug on and off, where and when we want, with single-cell precision," lead author Dirk Trauner said in a statement. "The upshot is that our compounds retain the powerful anticancer effects of existing microtubule inhibitors, but add the bonus of tissue-specific localization."

"The field of photopharmacology is very young, so it may take some time for the pharmaceutical industry to recognize the value of these compounds," co-author Oliver Thorn-Seshold said. "Yet, if our ongoing studies are successful, we will have a convincing proposition for further preclinical development, and we are committed to getting as far into real therapy as we can."

- here's the release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.